Sign in
Subscribe
    • Stock Lists
      arrow_drop_down
      • Longevity Stocks
      • COVID-19 Stocks
    • Longevity Trial Tracker
    • Newsletter
    • Resources
      arrow_drop_down
      • Events
      • Supporters
    • About
    Subscribe

    Organovo

    develops functional, 3D human tissue for medical research and therapeutic applications.

    • Profile
    • prev
    • next
    • Bookmark
    • Website
    • Share
    • prev
    • next
    $ONVO
    $1.66
    $0.0100
    0.61%

    Marketcap: $14.46M
    Volume: 7.62K

    Organovo Holdings, Inc.
    Symbol: ONVO
    Employees: 20
    Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
    Website https://www.organovo.com

    LongevityMarketcap.com 2021.

      • Facebook
      • Twitter
      • WhatsApp
      • Telegram
      • LinkedIn
      • Tumblr
      • VKontakte
      • Mail
      • Copy link